Total treatment before surgery for early rectal cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing and able to sign informed consent in writing
- Have rectal cancer confirmed as adenocarcinoma on biopsy
- Have cancer that has not spread to distant organs on scans, and surgery to remove it is possible
- Be 20 years or older, and have an activity level score (ECOG) of 0 to 1
- Have rectal cancer located within 12 cm of the anus, and be diagnosed as cT2N0M0 before starting treatment (based on scan and lymph node size/features)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This study follows real-world treatment of locally advanced rectal cancer (cancer that has grown into nearby tissues but hasn't spread to distant organs) in patients who receive chemotherapy and/or radiation before surgery. Researchers track how different treatment approaches work to help improve outcomes.
This study compares two standard treatment approaches for early-stage rectal cancer that has not spread. One group gets chemo and radiation before surgery, while the other gets chemo, radiation, and more chemo before surgery. The goal is to see which plan is more effective and has fewer side effects.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This Phase 3 trial compares two treatment plans given before rectal surgery. It tests whether stronger chemotherapy alone works better than chemotherapy pills plus long-term radiation to improve outcomes for locally advanced rectal cancer.
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.